Dermatomyositis

The FDA has granted rare pediatric disease designation to Descartes-08, an autologous mRNA cell therapy, for the treatment of juvenile dermatomyositis, Cartesian Therapeutics announced in a press release.

Enrollment in the phase 3 VALOR study evaluating brepocitinib for the treatment of dermatomyositis has been completed, Priovant Therapeutics announced in a press release.

ORLANDO, Fla. — Malignancies and lung involvement are the two key manifestations of dermatomyositis that require vigilance, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

CLEVELAND — Dermatomyositis treatment options could grow exponentially in the next few years, according to David Fiorentino, MD, PhD, professor of dermatology at Stanford University.

DESTIN, Fla. — Although the strongest predictor of malignancy in dermatomyositis is age, all adult patients should undergo cancer screening, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with myositis, according to a press release from the manufacturer.

DESTIN, Fla. — Although new targets and therapies are on the horizon, current myositis treatment strategies rely on treating impacted organ groups, according to a speaker at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Dermatomyositis and tinea are just two of many dermatologic complications that may resemble rheumatologic conditions, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

PHILADELPHIA — High risk factors for cancer in patients with idiopathic inflammatory myopathy include dermatomyositis, anti-TIF1-gamma positivity, anti-NXP2 positivity and age 40 or older at onset, said a speaker here.

Apremilast may be an efficacious and safe treatment option for patients with recalcitrant cutaneous dermatomyositis, according to a study.